Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether ifosfamide alone is more effective than
ifosfamide plus paclitaxel in treating patients with cancer of the uterus.
PURPOSE: Randomized phase III trial to compare the effectiveness of ifosfamide with or
without paclitaxel in treating patients with advanced, refractory, or recurrent cancer of the
uterus.
Phase:
Phase 3
Details
Lead Sponsor:
Gynecologic Oncology Group
Collaborators:
Eastern Cooperative Oncology Group National Cancer Institute (NCI)